Award
National Institute of Allergy and Infectious Diseases 1R44AI186932-01
Enhanced Seasonal Influenza Vaccine Targeting Variable and Conserved Antigens
Recipient
ORLANCE, INC.
Award Amount
$300,000.00
Ceiling
$300,000.00
Awarded
August 08, 2024
Identifier
1R44AI186932-01
Development of a universal influenza vaccine using DNA technology and gene gun delivery to improve efficacy against seasonal and pandemic strains, with testing in animal models.
Description
The project aims to develop a universal influenza vaccine using DNA technology and innovative delivery methods. The project includes phases of formulation comparison and efficacy testing in animal models. The vaccine combines a closely matched seasonal influenza DNA vaccine with a universal influenza DNA vaccine to provide broad protection. The gene gun delivery method is used to induce robust immune responses.